Middle East & Africa Gastrointestinal Drugs Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

Historic Data: 2021-2022   |   Base Year: 2023   |   Forecast Period: 2024-2031

Report Coverage:
  • Drug Class (Biologics, Antidiarrheal and Laxatives, Acid Neutralizers, Anti-inflammatory Drugs, Antiemetic and Antinauseants, Others)
  • Application (Irritable Bowel Syndrome, Inflammatory Ulcerative Colitis, Crohn\'s Disease, Gastroenteritis, Celiac Disease, Others)
  • Route Of Administration (Oral, Parenteral)
  • Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)


No. of Pages: 152    |    Report Code: TIPRE00016306    |    Category: Life Sciences

Explore in Your Language
Middle East & Africa Gastrointestinal Drugs Market
Buy Now

The Middle East & Africa gastrointestinal drugs market size is expected to reach US$ 2,889.26 million by 2031 from US$ 1,814.42 million in 2023. The market is estimated to record a CAGR of 6.0% from 2023 to 2031.

Executive Summary and Middle East & Africa Gastrointestinal Drugs Market Analysis:

Middle East & Africa consists of three major countries namely United Arab Emirates (UAE), Saudi Arabia, South Africa, and the Rest of MEA. Saudi Arabia is the largest market for gastrointestinal drugs. The market is driven by factors such as increasing government initiatives and rising in prevalence of gastrointestinal diseases.

Middle East & Africa Gastrointestinal Drugs Market Strategic Insights

global-market-strategic-framework
Get more information on this report

Middle East & Africa Gastrointestinal Drugs Market Segmentation Analysis

Key segments that contributed to the derivation of the gastrointestinal drugs market analysis are drug class, application, route of administration, and distribution channel.

  • Based on drug class, the Middle East & Africa gastrointestinal drugs market is segmented into biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants and others. The biologics held the largest share of the market in 2023.
  • By application, the Middle East & Africa gastrointestinal drugs market is segmented into irritable bowel syndrome, inflammatory ulcerative colitis, Crohn’s disease, gastroenteritis, celiac disease and others. The irritable bowel syndrome segment held the largest share of the market in 2023.
  • By route of administration, the Middle East & Africa gastrointestinal drugs market is bifurcated into oral and parenteral. The oral segment held a larger share of the market in 2023.
  • By distribution channel, the Middle East & Africa gastrointestinal drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2023.

Middle East & Africa Gastrointestinal Drugs Market Outlook

Companies operating in the gastrointestinal drugs market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them improve their sales, increase their geographic reach, and improve their capacities to cater to a greater than existing customer base. A few strategic initiatives taken by key players operating in the gastrointestinal drugs market are mentioned below:

  • In September 2023, Vivante Health closed US$ 31 million in a Series B funding round led by Mercato Partners, a new investor, to advance the digital digestive health platform. The new funding is mainly received due to the latest GIThrive platform enhancements that highlight the platform's unique ability to provide proper care at the right time. Series B Capital provides continued technological advancements designed to predict the onset and progression of gastrointestinal conditions and provide complete virtual care.
  • In May 2024, Strides Pharma Global Pte. Ltd received approval from the US FDA to market the generic version of Sucralfate Oral Suspension, 1gm/10 mL. The medication is used for the treatment of gastrointestinal diseases such as stomach ulcers, GERD, and stomach inflammation, as well as to help avoid stress ulcers.
  • In May 2020, Sanofi, a top manufacturer of brands such as Buscopan for Irritable Bowel Syndrome and Dulcolax for constipation relief, entered the digestive wellbeing market space with the introduction of a new food supplement, Buscobiota. Buscobiota contains three types of Lactobacillus and two types of Bifidobacterium, which can be utilized as a preventive medication for chronic constipation.

Therefore, strategic initiatives by various companies focusing on the development of drugs for the treatment of digestive diseases are likely to offer growth opportunities to the gastrointestinal drugs market in the coming years.

Middle East & Africa Gastrointestinal Drugs Market Country Insights

Based on country, the Middle East & Africa gastrointestinal drugs market comprises Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. South Africa held the largest share in 2023.

In South Africa, a variety of conditions remains undiagnosed, which highlights the need for awareness of diseases such as IBS, outlet dysfunction, constipation, and colon cancer symptoms, as well as the importance of early diagnosis. The issues associated with constipation increase with age. The South African Gastroenterology Society (SAGES) reports that older adults are five times more likely to develop constipation-related problems. According to the article titled “Everything You Need to Know about Irritable Bowel Syndrome,” published in March 2021, approximately 8% of the country’s population (~4.6 million South Africans) suffer from IBS, at least one day per week on average, in the last three months.

In recent years, new agents for constipation control have been introduced, requiring the shortcomings of current therapies, particularly for the treatment of opioid-induced constipation and other inflammatory bowel disorders or severe pelvic floor dysfunction. Several of these drugs are licensed and used in South Africa. For example, Lubiprostone is approved for adult chronic idiopathic constipation and opioid-induced constipation.

Middle East & Africa Gastrointestinal Drugs Market Report Highlights

Report Attribute Details
Market size in 2023 US$ 1,814.42 Million
Market Size by 2031 US$ 2,889.26 Million
Global CAGR (2023 - 2031) 6.0%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Drug Class
  • Biologics
  • Antidiarrheal and Laxatives
  • Acid Neutralizers
  • Anti-inflammatory Drugs
  • Antiemetic and Antinauseants
  • Others
By Application
  • Irritable Bowel Syndrome
  • Inflammatory Ulcerative Colitis
  • Crohn's Disease
  • Gastroenteritis
  • Celiac Disease
  • Others
By Route Of Administration
  • Oral
  • Parenteral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Regions and Countries Covered Middle East and Africa
  • Saudi Arabia
  • the UAE
  • South Africa
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Sanofi SA
  • GSK Plc
  • Johnson & Johnson
  • Bausch Health Companies Inc
  • AstraZeneca Plc
  • AbbVie Inc
  • Bayer AG
  • Pfizer Inc
  • Get more information on this report

    Middle East & Africa Gastrointestinal Drugs Market Company Profiles

    Some of the key players operating in the gastrointestinal drugs market include Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, AbbVie Inc, Bayer AG, and Pfizer Inc among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

    Middle East & Africa Gastrointestinal Drugs Market Research Methodology :

    The following methodology has been followed for the collection and analysis of data presented in this report:

    • Secondary Research

    The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

    • Company websites, annual reports, financial statements, broker analyses, and investor presentations.
    • Industry trade journals and other relevant publications.
    • Government documents, statistical databases, and market reports.
    • News articles, press releases, and webcasts specific to companies operating in the market.

    Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

    • Primary Research

    Business Market Insights’ conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis, and gain valuable insights. These research interviews are designed to:

    • Validate and refine findings from secondary research.
    • Enhance the expertise and market understanding of the analysis team.
    • Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

    Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

    • Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
    • External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

    Middle East & Africa Gastrointestinal Drugs Market Country and Regional Insights

    middle-east-and-africa-gastrointestinal-drugs-market
    Get more information on this report

    The List of Companies - Middle East & Africa Gastrointestinal Drugs Market

    1. Sanofi SA 
    2. GSK Plc
    3. Johnson & Johnson
    4. Bausch Health Companies Inc
    5. AstraZeneca Plc
    6. AbbVie Inc 
    7. Bayer AG 
    8. Pfizer Inc
    Frequently Asked Questions
    How big is the Middle East & Africa Gastrointestinal Drugs Market?

    The Middle East & Africa Gastrointestinal Drugs Market is valued at US$ 1,814.42 Million in 2023, it is projected to reach US$ 2,889.26 Million by 2031.

    What is the CAGR for Middle East & Africa Gastrointestinal Drugs Market by (2023 - 2031)?

    As per our report Middle East & Africa Gastrointestinal Drugs Market, the market size is valued at US$ 1,814.42 Million in 2023, projecting it to reach US$ 2,889.26 Million by 2031. This translates to a CAGR of approximately 6.0% during the forecast period.

    What segments are covered in this report?

    The Middle East & Africa Gastrointestinal Drugs Market report typically cover these key segments-

    • Drug Class (Biologics, Antidiarrheal and Laxatives, Acid Neutralizers, Anti-inflammatory Drugs, Antiemetic and Antinauseants, Others)
    • Application (Irritable Bowel Syndrome, Inflammatory Ulcerative Colitis, Crohn\'s Disease, Gastroenteritis, Celiac Disease, Others)
    • Route Of Administration (Oral, Parenteral)
    • Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

    What is the historic period, base year, and forecast period taken for Middle East & Africa Gastrointestinal Drugs Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Gastrointestinal Drugs Market report:

  • Historic Period : 2021-2022
  • Base Year : 2023
  • Forecast Period : 2024-2031
  • Who are the major players in Middle East & Africa Gastrointestinal Drugs Market?

    The Middle East & Africa Gastrointestinal Drugs Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Sanofi SA
  • GSK Plc
  • Johnson & Johnson
  • Bausch Health Companies Inc
  • AstraZeneca Plc
  • AbbVie Inc
  • Bayer AG
  • Pfizer Inc
  • Who should buy this report?

    The Middle East & Africa Gastrointestinal Drugs Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Middle East & Africa Gastrointestinal Drugs Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now